Phase 3Completed
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia
- Sponsor
- LG Life Sciences (Industry)
- Enrollment
- 168 enrolled
- Conditions
- Hypertension,; Hyperlipidemia
- Interventions
- Valsartan 160mg; Rosuvastatin 20mg; Valsartan 160mg placebo; Rosuvastatin 20mg placebo
- Ages
- adults, older adults
- Registry
- NCT01918332
Full record on ClinicalTrials.gov
From the registry
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.
Primary outcomes
- sitDBP Changes at Week 8 From Baseline
- LDL-C Percentage Changes at Week 8 From Baseline
History
Results first posted
Last registry update
Registered
Primary completion
Started